Agentic AI is being hailed across the revenue cycle right now, for appeals, claim resubmissions, documentation retrieval and a slew of other workflows. For the most part, the use cases make sense on paper. But many health system revenue cycle teams are making deployment decisions based on the wrong signal, which process takes the most staff time. The intent is to address a real workload problem, but it’s not the same as knowing where automation will actually lead to measurable ROI.
AI Agents are only as smart as what they’re aimed at. Without an intelligence layer underneath the decision, you’re automating based on volume and instinct, which is an expensive way to find out you started in the wrong place.
Sift equips health systems with advanced analytics that cut through the volumes of claim submissions, complex adjudications and aged AR to highlight where organizations can gain the most value from Agentic AI.
Before you commit engineering resources or engage a third party in a costly SOW to any denial cluster, review your reimbursement reports and denials data and ask three questions.
1. What’s the overturn rate when this denial type is actually worked? If your team appeals a specific denial cluster and wins more than 50% of the time, that’s a strong automation candidate. The pattern is predictable enough for an agent to follow. If the overturn rate is low or inconsistent, you’re not looking at an automation problem. You’re looking at an internal process or payer behavior problem that needs a different fix first.
2. Is the root cause upstream or at the claim level? Some denial clusters trace back to eligibility/verification challenges, authorization misses, or coding patterns that repeat. If the root cause is upstream, automating the appeals process won’t stop the volume; you’ll just be running a faster hamster wheel. Right now, the clusters worth automating are the ones where the denial is the end of the story, not a symptom of something earlier.
3. How does this payer behave on this denial type specifically? Payers aren’t consistent across denial categories. A payer that responds well to appeals on DRG downgrades may be a dead end on clinical validation denials. Before you build agent logic around a payer interaction, check whether that specific payer has a track record of responding and reversing on that specific denial type. If they don’t, you’re automating a process that leads nowhere.
The teams we see getting real value from automation right now didn’t start with the shiniest use case. They started with what their data supported, looking at which clusters convert from denial to recovery, how/which payers respond and where the root cause actually lives. The intelligence layer has to come before the automation layer, or you’re just moving faster without getting any closer to your destination
Want help running this analysis on your own denial data? That’s what Sift’s RevProtect Payments Intelligence Platform is built for.
